{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:25:19Z","timestamp":1792686319587,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972630"],"award-info":[{"award-number":["81972630"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372842"],"award-info":[{"award-number":["82372842"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>While the p53 upregulated modulator of apoptosis (PUMA) is traditionally recognized for promoting cell apoptosis and enhancing chemotherapy efficacy in various cancers, its role in clear cell renal cell carcinoma (ccRCC) remains unclear due to ccRCC\u2019s chemotherapy resistance. In this study, we discover a novel oncogenic role for PUMA in ccRCC, diverging from its known apoptotic function, through assessments of public datasets, clinical tissue samples, and cell line experiments. Abnormally high expression of PUMA positively correlates with clinical stages and poor prognosis. Notably, PUMA\u2019s role in ccRCC appears to be independent of apoptosis. Instead, it facilitates tumor progression and lipid accumulation through mechanisms involving the key metabolic regulator, fatty acid synthase (FASN). Specifically, the N44-102 amino acid sequence of PUMA, distinct from the previously studied BH3 domain, is crucial for its interaction with FASN. As a mechanism, PUMA stabilizes FASN by binding to ubiquitin-specific protease 15 (USP15), reducing FASN ubiquitination and degradation, thereby forming the PUMA-USP15-FASN axis. These findings challenge the established view of PUMA\u2019s role in cancer biology. Furthermore, PUMA knockdown significantly inhibits tumor growth and enhances the sensitivity of ccRCC tumors to metabolic inhibition. These results position PUMA as a novel metabolic regulator and a potential therapeutic target in ccRCC. The combined inhibition of PUMA and FASN further supports the therapeutic potential of targeting this metabolic axis.<\/jats:p>","DOI":"10.1038\/s41419-025-07782-y","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T23:05:16Z","timestamp":1750287916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["PUMA reduces FASN ubiquitination to promote lipid accumulation and tumor progression in human clear cell renal cell carcinoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Qianqian","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"LV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0924-5795","authenticated-orcid":false,"given":"Hongmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"7782_CR1","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.3390\/cancers14133278","volume":"14","author":"EM Bajalia","year":"2022","unstructured":"Bajalia EM, Azzouz FB, Chism DA, Giansiracusa DM, Wong CG, Plaskett KN, et al. Phytochemicals for the prevention and treatment of renal cell carcinoma: preclinical and clinical evidence and molecular mechanisms. Cancers. 2022;14:3278.","journal-title":"Cancers"},{"key":"7782_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA-Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA-Cancer J Clin"},{"key":"7782_CR3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","volume":"26","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Kaelin WG. Targeting the HIF2\u2013VEGF axis in renal cell carcinoma. Nat Med. 2020;26:1519\u201330.","journal-title":"Nat Med"},{"key":"7782_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"The Cancer Genome Atlas Research Network.","year":"2013","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43\u201349.","journal-title":"Nature"},{"key":"7782_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1210\/endrev\/bnac025","volume":"44","author":"RA Toledo","year":"2022","unstructured":"Toledo RA, Jimenez C, Armaiz-Pena G, Arenillas C, Capdevila J, Dahia PLM. Hypoxia-inducible factor 2 alpha (HIF2\u03b1) inhibitors: targeting genetically driven tumor hypoxia. Endocr Rev. 2022;44:312\u201322.","journal-title":"Endocr Rev"},{"key":"7782_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3322\/caac.21411","volume":"67","author":"PC Barata","year":"2017","unstructured":"Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA-Cancer J Clin. 2017;67:507\u201324.","journal-title":"CA-Cancer J Clin"},{"key":"7782_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10555-021-09996-w","volume":"41","author":"G Heravi","year":"2022","unstructured":"Heravi G, Yazdanpanah O, Podgorski I, Matherly LH, Liu W. Lipid metabolism reprogramming in renal cell carcinoma. Cancer Metastasis Rev. 2022;41:17\u201331.","journal-title":"Cancer Metastasis Rev"},{"key":"7782_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.610229","volume":"7","author":"W Xu","year":"2021","unstructured":"Xu W, Hu X, Anwaier A, Wang J, Liu W, Tian X, et al. Fatty acid synthase correlates with prognosis-related abdominal adipose distribution and metabolic disorders of clear cell renal cell carcinoma. Front Mol Biosci. 2021;7:610229.","journal-title":"Front Mol Biosci"},{"key":"7782_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.264","volume":"11","author":"Z Xiong","year":"2021","unstructured":"Xiong Z, Xiong W, Xiao W, Yuan C, Shi J, Huang Y, et al. NNT-induced tumor cell \u201cslimming\u201d reverses the pro-carcinogenesis effect of HIF2\u03b1 in tumors. Clin Transl Med. 2021;11:e264.","journal-title":"Clin Transl Med"},{"key":"7782_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01965-8","volume":"8","author":"W Du","year":"2017","unstructured":"Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel CL, et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun. 2017;8:1769.","journal-title":"Nat Commun"},{"key":"7782_CR11","doi-asserted-by":"publisher","DOI":"10.34133\/research.0322","volume":"7","author":"J Shi","year":"2024","unstructured":"Shi J, Lv Q, Miao D, Xiong Z, Wei Z, Wu S, et al. HIF2\u03b1 promotes cancer metastasis through TCF7L2-dependent fatty acid synthesis in ccRCC. Research. 2024;7:0322.","journal-title":"Research"},{"key":"7782_CR12","doi-asserted-by":"publisher","first-page":"a026096","DOI":"10.1101\/cshperspect.a026096","volume":"6","author":"CM Eischen","year":"2016","unstructured":"Eischen CM. Genome stability requires p53. Cold Spring Harb Perspect Med. 2016;6:a026096.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"7782_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20:471\u201380.","journal-title":"Nat Rev Cancer"},{"key":"7782_CR14","first-page":"32","volume":"1870","author":"CF Labuschagne","year":"2018","unstructured":"Labuschagne CF, Zani F, Vousden KH. Control of metabolism by p53\u2014cancer and beyond. BBA-Rev Cancer. 2018;1870:32\u201342.","journal-title":"BBA-Rev Cancer"},{"key":"7782_CR15","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1038\/onc.2012.640","volume":"32","author":"A Rufini","year":"2013","unstructured":"Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. Oncogene. 2013;32:5129\u201343.","journal-title":"Oncogene"},{"key":"7782_CR16","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/emmm.201202231","volume":"5","author":"J Albers","year":"2013","unstructured":"Albers J, Rajski M, Sch\u00f6nenberger D, Harlander S, Schraml P, Von Teichman A, et al. Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice. EMBO Mol Med. 2013;5:949\u201364.","journal-title":"EMBO Mol Med"},{"key":"7782_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13608-1","volume":"10","author":"W Cai","year":"2019","unstructured":"Cai W, Su L, Liao L, Liu ZZ, Langbein L, Dulaimi E, et al. PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nat Commun. 2019;10:5800.","journal-title":"Nat Commun"},{"key":"7782_CR18","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00432-021-03786-1","volume":"147","author":"K Diesing","year":"2021","unstructured":"Diesing K, Ribback S, Winter S, Gellert M, Oster AM, St\u00fchler V, et al. p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics. J Cancer Res Clin Oncol. 2021;147:3565\u201376.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7782_CR19","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.3390\/cancers14235733","volume":"14","author":"A Amendolare","year":"2022","unstructured":"Amendolare A, Marzano F, Petruzzella V, Vacca RA, Guerrini L, Pesole G, et al. The underestimated role of the p53 pathway in renal cancer. Cancers. 2022;14:5733.","journal-title":"Cancers"},{"key":"7782_CR20","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1038\/onc.2009.45","volume":"27","author":"J Yu","year":"2008","unstructured":"Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene. 2008;27:S71\u2013S83.","journal-title":"Oncogene"},{"key":"7782_CR21","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.neo.2014.09.012","volume":"16","author":"X Zhou","year":"2014","unstructured":"Zhou X, Tolstov Y, Arslan A, Roth W, Grullich C, Pahernik S, et al. Harnessing the p53\u2013PUMA axis to overcome DNA damage resistance in renal cell carcinoma. Neoplasia. 2014;16:1028\u201335.","journal-title":"Neoplasia"},{"key":"7782_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2478\/s11658-012-0032-5","volume":"17","author":"P Hikisz","year":"2012","unstructured":"Hikisz P, Kilianska ZM. PUMA, a critical mediator of cell death-one decade on from its discovery. Cell Mol Biol Lett. 2012;17:646\u201369.","journal-title":"Cell Mol Biol Lett"},{"key":"7782_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ccell.2018.12.012","volume":"35","author":"J Kim","year":"2019","unstructured":"Kim J, Yu L, Chen W, Xu Y, Wu M, Todorova D, et al. Wild-type p53 promotes cancer metabolic switch by inducing PUMA-dependent suppression of oxidative phosphorylation. Cancer Cell. 2019;35:191\u2013203.","journal-title":"Cancer Cell"},{"key":"7782_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10495-021-01667-z","volume":"26","author":"M Li","year":"2021","unstructured":"Li M. The role of P53 up-regulated modulator of apoptosis (PUMA) in ovarian development, cardiovascular and neurodegenerative diseases. Apoptosis. 2021;26:235\u201347.","journal-title":"Apoptosis"},{"key":"7782_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cgt.2012.84","volume":"20","author":"LN Zhang","year":"2013","unstructured":"Zhang LN, Li JY, Xu W. A review of the role of PUMA, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene Ther. 2013;20:1\u20137.","journal-title":"Cancer Gene Ther"},{"key":"7782_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mc.21842","volume":"52","author":"TY Yang","year":"2013","unstructured":"Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, Wu CH, et al. Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated\/p53-dependent and -independent signaling pathways. Mol Carcinog. 2013;52:183\u201394.","journal-title":"Mol Carcinog"},{"key":"7782_CR27","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s10620-007-9799-z","volume":"52","author":"MR Kim","year":"2007","unstructured":"Kim MR, Jeong EG, Chae B, Lee JW, Soung YH, Nam SW, et al. Pro-apoptotic PUMA and anti-apoptotic phospho-BAD are highly expressed in colorectal carcinomas. Dig Dis Sci. 2007;52:2751\u20136.","journal-title":"Dig Dis Sci"},{"key":"7782_CR28","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s12094-013-1010-8","volume":"15","author":"W Cai","year":"2013","unstructured":"Cai W, Li Q, Yang Z, Miao X, Wen Y, Huang S, et al. Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance. Clin Transl Oncol. 2013;15:818\u201324.","journal-title":"Clin Transl Oncol"},{"key":"7782_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.tranon.2015.11.003","volume":"8","author":"X Zhou","year":"2015","unstructured":"Zhou X, Li J, Marx C, Tolstov Y, Rauch G, Herpel E, et al. Uncoupling of PUMA expression and apoptosis contributes to functional heterogeneity in renal cell carcinoma - prognostic and translational implications. Transl Oncol. 2015;8:480\u20136.","journal-title":"Transl Oncol"},{"key":"7782_CR30","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.celrep.2012.09.023","volume":"5","author":"F Zhang","year":"2012","unstructured":"Zhang F, Li Y, Tang Z, Kumar A, Lee C, Zhang L, et al. Proliferative and survival effects of PUMA promote angiogenesis. Cell Rep. 2012;5:1272\u201385.","journal-title":"Cell Rep"},{"key":"7782_CR31","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1158\/1078-0432.CCR-19-0396","volume":"26","author":"Q Cao","year":"2020","unstructured":"Cao Q, Song Z, Ruan H, Wang C, Yang X, Bao L, et al. Targeting the KIF4A\/AR axis to reverse endocrine therapy resistance in castration-resistant prostate cancer. Clin Cancer Res. 2020;26:1516\u201328.","journal-title":"Clin Cancer Res"},{"key":"7782_CR32","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013W102.","journal-title":"Nucleic Acids Res"},{"key":"7782_CR33","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, Mcdade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675\u20138.","journal-title":"Nat Biotechnol"},{"key":"7782_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-016-0565-8","volume":"15","author":"KK Brodaczewska","year":"2016","unstructured":"Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C, Czarnecka AM. Choosing the right cell line for renal cell cancer research. Mol Cancer. 2016;15:1\u201315.","journal-title":"Mol Cancer"},{"key":"7782_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:1\u201319.","journal-title":"Nat Rev Dis Primers"},{"key":"7782_CR36","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/cr.2017.41","volume":"27","author":"X Liu","year":"2017","unstructured":"Liu X, Li F, Huang Q, Zhang Z, Zhou L, Deng Y, et al. Self-inflicted DNA double-strand breaks sustain tumorigenicity and stemness of cancer cells. Cell Res. 2017;27:764\u201383.","journal-title":"Cell Res"},{"key":"7782_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04768-y","volume":"13","author":"A Haimovici","year":"2022","unstructured":"Haimovici A, H\u00f6fer C, Badr MT, Bavafaye Haghighi E, Amer T, Boerries M, et al. Spontaneous activity of the mitochondrial apoptosis pathway drives chromosomal defects, the appearance of micronuclei and cancer metastasis through the Caspase-Activated DNAse. Cell Death Dis. 2022;13:315.","journal-title":"Cell Death Dis"},{"key":"7782_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/cr.2017.155","volume":"28","author":"PE Porporato","year":"2018","unstructured":"Porporato PE, Filigheddu N, Pedro JMB-S, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28:265\u201380.","journal-title":"Cell Res"},{"key":"7782_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nature10642","volume":"481","author":"AR Mullen","year":"2012","unstructured":"Mullen AR, Wheaton WW, Jin ES, Chen P-H, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2012;481:385\u20138.","journal-title":"Nature"},{"key":"7782_CR40","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.88329","volume":"12","author":"JM Pemberton","year":"2023","unstructured":"Pemberton JM, Nguyen D, Osterlund EJ, Schormann W, Pogmore JP, Hirmiz N, et al. The carboxyl-terminal sequence of PUMA binds to both anti-apoptotic proteins and membranes. Elife. 2023;12:e88329.","journal-title":"Elife"},{"key":"7782_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153227","volume":"216","author":"Y Yuan","year":"2020","unstructured":"Yuan Y, Yang X, Li Y, Liu Q, Wu F, Qu H, et al. Expression and prognostic significance of fatty acid synthase in clear cell renal cell carcinoma. Pathol Res Pract. 2020;216:153227.","journal-title":"Pathol Res Pract"},{"key":"7782_CR42","doi-asserted-by":"publisher","first-page":"6924","DOI":"10.1158\/0008-5472.CAN-16-1597","volume":"76","author":"HP Lin","year":"2016","unstructured":"Lin HP, Cheng ZL, He RY, Song L, Tian MX, Zhou LS, et al. Destabilization of fatty acid synthase by acetylation inhibits de novo lipogenesis and tumor cell growth. Cancer Res. 2016;76:6924\u201336.","journal-title":"Cancer Res"},{"key":"7782_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40975-7","volume":"14","author":"Z Gong","year":"2023","unstructured":"Gong Z, Zhu J, Chen J, Feng F, Zhang H, Zhang Z, et al. CircRREB1 mediates lipid metabolism related senescent phenotypes in chondrocytes through FASN post-translational modifications. Nat Commun. 2023;14:5242.","journal-title":"Nat Commun"},{"key":"7782_CR44","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3389\/fphar.2019.00709","volume":"10","author":"N Yang","year":"2019","unstructured":"Yang N, Li C, Li H, Liu M, Cai X, Cao F, et al. Emodin induced SREBP1-dependent and SREBP1-independent apoptosis in hepatocellular carcinoma cells. Front Pharmacol. 2019;10:709.","journal-title":"Front Pharmacol"},{"key":"7782_CR45","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1158\/0008-5472.CAN-19-3718","volume":"80","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Zhou H, Ponzoni L, Luo A, Zhu R, He M, et al. EIF3H orchestrates Hippo pathway-mediated oncogenesis via catalytic control of YAP stability. Cancer Res. 2020;80:2550\u201363.","journal-title":"Cancer Res"},{"key":"7782_CR46","first-page":"973","volume":"18","author":"A Vazquez-Martin","year":"2007","unstructured":"Vazquez-Martin A, Ropero S, Brunet J, Colomer R, Menendez JA. Inhibition of fatty acid synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Oncol Rep. 2007;18:973\u201380.","journal-title":"Oncol Rep"},{"key":"7782_CR47","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32:2866\u20138.","journal-title":"Bioinformatics"},{"key":"7782_CR48","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","volume":"17","author":"P Makhov","year":"2018","unstructured":"Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Mol Cancer Ther. 2018;17:1355\u201364.","journal-title":"Mol Cancer Ther"},{"key":"7782_CR49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41585-022-00654-6","volume":"20","author":"SK Tan","year":"2023","unstructured":"Tan SK, Hougen HY, Merchan JR, Gonzalgo ML, Welford SM. Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets. Nat Rev Urol. 2023;20:48\u201360.","journal-title":"Nat Rev Urol"},{"key":"7782_CR50","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1038\/onc.2011.36","volume":"30","author":"CG Roberts","year":"2011","unstructured":"Roberts CG, Millar EKA, O\u2019Toole SA, McNeil CM, Lehrbach GM, Pinese M, et al. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene. 2011;30:3186\u201397.","journal-title":"Oncogene"},{"key":"7782_CR51","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1158\/1078-0432.CCR-15-3133","volume":"22","author":"A Gir\u00f3-Perafita","year":"2016","unstructured":"Gir\u00f3-Perafita A, Palomeras S, Lum DH, Blancafort A, Vi\u00f1as G, Oliveras G, et al. Preclinical evaluation of fatty acid synthase and EGFR inhibition in triple-negative breast cancer. Clin Cancer Res. 2016;22:4687\u201397.","journal-title":"Clin Cancer Res"},{"key":"7782_CR52","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1038\/s41388-020-1156-0","volume":"39","author":"L Gu","year":"2020","unstructured":"Gu L, Zhu Y, Lin X, Tan X, Lu B, Li Y. Stabilization of FASN by ACAT1-mediated GNPAT acetylation promotes lipid metabolism and hepatocarcinogenesis. Oncogene. 2020;39:2437\u201349.","journal-title":"Oncogene"},{"key":"7782_CR53","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41392-023-01405-8","volume":"8","author":"W Wei","year":"2023","unstructured":"Wei W, Qin B, Wen W, Zhang B, Luo H, Wang Y, et al. FBXW7\u03b2 loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth. Sig Transduct Target Ther. 2023;8:187.","journal-title":"Sig Transduct Target Ther"},{"key":"7782_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07185-y","volume":"9","author":"B Liu","year":"2018","unstructured":"Liu B, Jiang S, Li M, Xiong X, Zhu M, Li D, et al. Proteome-wide analysis of USP14 substrates revealed its role in hepatosteatosis via stabilization of FASN. Nat Commun. 2018;9:4770.","journal-title":"Nat Commun"},{"key":"7782_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.899987","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Lin W, Li R, Cheng H, Sun S, Shao F, et al. The deubiquitinase USP13 maintains cancer cell stemness by promoting FASN stability in small cell lung cancer. Front Oncol. 2022;12:899987.","journal-title":"Front Oncol"},{"key":"7782_CR56","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1535-6108(04)00055-8","volume":"5","author":"E Graner","year":"2004","unstructured":"Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer cell. 2004;5:253\u201361.","journal-title":"Cancer cell"},{"key":"7782_CR57","first-page":"2686","volume":"12","author":"Z Zheng","year":"2022","unstructured":"Zheng Z, Shang Y, Xu R, Yan X, Wang X, Cai J, et al. Ubiquitin specific peptidase 38 promotes the progression of gastric cancer through upregulation of fatty acid synthase. Am J Cancer Res. 2022;12:2686\u201396.","journal-title":"Am J Cancer Res"},{"key":"7782_CR58","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.juro.2008.03.186","volume":"180","author":"A Horiguchi","year":"2008","unstructured":"Horiguchi A, Asano T, Asano T, Ito K, Sumitomo M, Hayakawa M. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells. J Urology. 2008;180:729\u201336.","journal-title":"J Urology"},{"key":"7782_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1258096.","journal-title":"Science"},{"key":"7782_CR60","doi-asserted-by":"publisher","first-page":"D719","DOI":"10.1093\/nar\/gkab962","volume":"50","author":"X Wang","year":"2022","unstructured":"Wang X, Li Y, He M, Kong X, Jiang P, Liu X, et al. Ubibrowser 2.0: a comprehensive resource for proteome-wide known and predicted ubiquitin ligase\/deubiquitinase\u2013substrate interactions in eukaryotic species. Nucleic Acids Res. 2022;50:D719\u2013D728.","journal-title":"Nucleic Acids Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07782-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:02:59Z","timestamp":1750291379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07782-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7782"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07782-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"6 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"(a) All methods in this study were performed in accordance with the relevant guidelines and regulations. (b) For animal experiments, approval was obtained from the Institutional Animal Care and Use Committee (IACUC) of Huazhong University of Science and Technology with approval number 3617. For human studies, approval was obtained from the Institutional Ethics Committee (IEC) of Tongji Medical College, Huazhong University of Science and Technology, Union Hospital with the reference number 0847. (c) Informed consent was obtained from all participants involved in the human studies. (d) No identifiable images from human research participants were included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and Consent to participate"}}],"article-number":"460"}}